HC Wainwright set a $30.00 target price on Abeona Therapeutics (NASDAQ:ABEO) in a research note published on Thursday, January 4th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on the stock. ValuEngine lowered shares of Abeona Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Zacks Investment Research lowered shares of Abeona Therapeutics from a buy rating to a hold rating in a report on Thursday, November 23rd. Jefferies Group restated a buy rating and issued a $28.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. Maxim Group set a $35.00 price objective on shares of Abeona Therapeutics and gave the stock a buy rating in a report on Monday, November 20th. Finally, SunTrust Banks initiated coverage on shares of Abeona Therapeutics in a report on Wednesday, November 8th. They set a buy rating and a $26.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $26.40.

Shares of Abeona Therapeutics (ABEO) opened at $16.30 on Thursday. Abeona Therapeutics has a 12 month low of $4.50 and a 12 month high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. analysts expect that Abeona Therapeutics will post -0.6 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Geode Capital Management LLC raised its holdings in Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares during the period. Schwab Charles Investment Management Inc. purchased a new position in Abeona Therapeutics in the second quarter valued at approximately $264,000. Rhumbline Advisers acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $190,000. State of Wisconsin Investment Board acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $122,000. Finally, Bank of New York Mellon Corp grew its position in Abeona Therapeutics by 138.5% in the second quarter. Bank of New York Mellon Corp now owns 99,996 shares of the biopharmaceutical company’s stock valued at $640,000 after acquiring an additional 58,067 shares in the last quarter. Hedge funds and other institutional investors own 41.97% of the company’s stock.

WARNING: This article was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.mareainformativa.com/hc-wainwright-analysts-give-abeona-therapeutics-abeo-a-30-00-price-target-updated-updated-updated/125971/.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.